REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) > Bacterium Or Component Thereof Or Substance Produced By Said Bacterium (e.g., Legionella, Borrelia, Anaplasma, Shigella, Etc.) > Mycobacterium (e.g., Mycobacterium Tuberculosis, Calmette-guerin Bacillus (i.e., Bcg), Etc.) Mycobacterium (e.g., Mycobacterium Tuberculosis, Calmette-guerin Bacillus (i.e., Bcg), Etc.)Mycobacterium (e.g., Mycobacterium Tuberculosis, Calmette-guerin Bacillus (i.e., Bcg), Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.06/21/07 - 20070141087 - Compounds and methods for diagnosis of tuberculosis Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for ... 06/21/07 - 20070141086 - Use of antibiotics as vaccine adjuvants The invention describes an adjuvant composition comprising an antimicrobial agent, in particular an azalide, wherein the antimicrobial agent acts as an adjuvant. More particularly, the adjuvant composition is a vaccine adjuvant. The invention further describes a vaccine comprising several components comprising (a) at least one antigen and (b) at least ... 06/14/07 - 20070134274 - Vaccine candidates against johne's disease A composition and method for immunizing a mammal infected with Mycobacterium are disclosed. The genes gcpE, psta, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, and map1634 of M. paratuberculosis and the products that they encode are vaccine targets for Johne's and Crohn's disease. Eighteen M. paratuberculosis-specific ... 06/14/07 - 20070134273 - Composition and method for the treatment of carcinoma The present invention relates to compositions and methods useful for treating a carcinoma or viral infection in mammals, including humans. The methods and compositions typically comprise use of an immunogenic or immunomodulatory compound, and a gamma delta T cell activator, such that the composition is effective for treating a carcinoma ... 05/17/07 - 20070110770 - Apolipoprotein e as an adjuvant for lipid antigens The present invention is directed to pharmaceutical compositions that contain a combination of apolipoprotein E and an antigenic lipid. The compositions may be administered to a subject for the purpose of inducing an immune response against the lipid and in immunization protocols. ... 03/15/07 - 20070059328 - Process for manufacturing pharmaceutical composition comprises of mycobacterium w in the treatment of asthma (obstructive lung disease) The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the management of bronchial Asthma (obstructive lung disease). ... 02/01/07 - 20070026020 - Modified mycobacterium tuberculosis strains and uses thereof The present invention features modified Mycobacterium tuberculosis strains which lack a functional lspA gene, and vaccine formulations comprising the same. In many embodiments, a modified Mycobacterium tuberculosis strain of the invention comprises deletion or inactivation of the lspA gene and/or one or more non-lspA genes that are involved in Mycobacterium ... 12/21/06 - 20060286128 - Adjuvant combinations of liposomes and mycobacteriaial lipids for immunization compositions and vaccines The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <The present invention provides a vaccine ... 08/31/06 - 20060193876 - Fusion proteins of mycobacterium tuberculosis The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and ... 08/31/06 - 20060193875 - Method of treating human-immunodeficiency virus (hiv) disease infection Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. ... 08/03/06 - 20060171965 - Fusion proteins of mycobacterium tuberculosis The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and ... 07/13/06 - 20060153880 - Pharmaceutical use of alpha antigen or alpha antigen gene The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of ... 07/06/06 - 20060147473 - Mycobacterium cell wall composition The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the ... 06/29/06 - 20060140982 - Tuberculosis nucleic acids, polypeptides and immunogenic compositions The present invention provides transcriptionally active Mtb polynucleotides, recombinant Mtb peptides and polypeptides, and immunogenic Mtb antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides diagnostic kits for Mtb. ... 06/01/06 - 20060115497 - Mycobacterium strains with modified erp gene and vaccine composition containing same The invention concerns Mycobacterium strains whereof the erp gene is modified and a vaccine composition containing same. The modification of the erp gene decreases the virulence and the persistence of the Mycobacterium strains. ... 02/09/06 - 20060029620 - Mycobacterium smegmatis vaccine The present invention is about a mycobacterium smegmatis vaccine, a split product of mycobacterium smegmatis. This vaccine has made good use of the adjuvant function of bacterial cellwall and antigenic specificity of tropina which can stimulate the production of cytokine and consists of many immunologically competent CpG fragments of bacteria ... 02/02/06 - 20060024332 - Recombinant esat-6:cfp-10 fusion protein useful for specific diagnosis of tuberculosis The fusion protein rESAT-6:CFP-10 is useful for differentiating infection of an animal with Mycobacterium bovis from exposure of the animal to other species of Mycobacteria, especially M. avium and M. avium subspecies paratuberculosis (Map). Cells stimulated with the fusion protein are capable of eliciting a variety of in vivo and ... 11/24/05 - 20050260232 - Attenuated mycobacterium tuberculosis vaccines Non-naturally occurring mycobacteria in the Mycobacterium tuberculosis complex are provided. These mycobacteria have a deletion of an RD1 region or a region controlling production of a vitamin, and exhibit attenuated virulence in a mammal when compared to the mycobacteria without the deletion. Also provided are non-naturally occurring mycobacteria that have ... 06/02/05 - 20050118201 - Mycobacterial vaccine Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome® adjuvant, as well as methods for using such compositions. ... 06/02/05 - 20050118200 - Vaccines for mycoplasma bovis and methods of use The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of ... ### FreshPatents.com Support |